What TropIQ Health Sciences does

TropIQ Health Sciences is a Netherlands-based contract research organisation that provides specialised drug discovery and development services targeting vector-borne diseases — including malaria, dengue, Zika, Lyme disease, and West Nile virus — with an emphasis on interventions relevant to low- and middle-income countries. Founded in 2011 as a spin-off of Radboud University Medical Center and headquartered in Nijmegen, the company operates a single facility integrating microbiology and entomology expertise with laboratory automation, including semi-automated cell culture, vector labs for arthropod experiments, and liquid handling plus signal detection systems. Service offerings span high-throughput screening (enzyme assays, in vivo arthropod testing, anti-parasitic compounds, insect repellents), medicinal-chemistry Structure-Activity Relationship analysis, and genetic/molecular mechanism-of-action studies, with machine learning applied to molecule discovery and data analysis.

The company serves pharmaceutical companies, biotechnology firms, and academic research institutions — including the Malaria Drug Accelerator consortium — through direct enterprise sales, with the co-founder transitioning from CEO to a dedicated VP of Business Development role in 2024 alongside the appointment of a new CEO with two decades of biomedical/pharmaceutical B2B experience. TropIQ generates revenue through project-based professional services engagements, with pricing not publicly disclosed, and operates globally while being formally domiciled and resourced solely in the Netherlands. The business model is founder-controlled, with no disclosed venture, private equity, or institutional funding rounds in the available record, and growth is signalled primarily through peer-reviewed publications and consortium participation rather than disclosed financial metrics.

Name

TropIQ Health Sciences

Legal name

TropIQ Health Sciences

Website

https://tropiq.nl

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

TropIQ Health Sciences is a Netherlands-based contract research organisation providing high-throughput screening, medicinal chemistry, and mechanism-of-action services for drug discovery against vector-borne diseases such as malaria and dengue, serving pharmaceutical companies, biotech firms, and academic research institutions.

Ownership category

akta.pro rank

Product category

Contract Research Services for Drug Discovery

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Contract research services
• Vector-borne disease research
• High-throughput screening
• Malaria drug discovery
• Antimicrobial screening platform

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: TropIQ offers premium contract research services designed to fast-track the discovery and development of interventions against pathogens and arthropod vectors. Services include screening across various modalities, SAR analysis, and mechanism of action studies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

TropIQ Health Sciences provides premium contract research services for the accelerated discovery and development of interventions against vector-borne diseases, with a focus on malaria, dengue, Zika, and tick-borne illnesses affecting low and middle-income countries. The company operates a technology platform combining semi-automated cell culture, specialized vector labs, high-throughput screening, medicinal chemistry SAR analysis, and mechanism of action studies, integrated with advanced machine learning. Customers are pharmaceutical companies, biotech firms, and academic research institutions requiring specialized entomology and microbiology expertise for screening small molecules and biologicals.

Product overview

TropIQ Health Sciences offers a unified technology platform combining contract research services for vector-borne disease intervention discovery. The core offering consists of a high-throughput screening platform utilizing semi-automated cell culture, vector labs, and advanced signal detection equipment. This is supplemented by medicinal chemistry SAR analysis services and genetic/molecular mechanism of action studies. The platform screens enzyme assays, in vivo arthropod tests, anti-parasitic compounds, and insect repellents across varying throughput scales. All capabilities are powered by machine learning technologies for molecule discovery and data analysis efficiency.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Fluralaner showed mosquitocidal IC50 values ranging from 44 to 87 nM when mortality was assessed at 24 hours post-feeding
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• NPJ Drug Discovery (Nature Portfolio)coreStrategic or Co-development Partner · 1 January 2025TropIQ co-authored a publication in NPJ Drug Discovery on prioritisation of novel molecular targets for malaria drug discovery. The study involved expert review and rubric-based scoring of 540 potential targets in collaboration with a large group of researchers.
• Collaborators from Burkina Faso and NetherlandscoreStrategic or Co-development Partner · 1 January 2025Collaborative study with colleagues from Burkina Faso and the Netherlands on developing isoxazolines as mosquitocidal drugs for reduction of malaria disease incidence. The study validated that isoxazoline efficacy is unaffected by mosquito microbiome changes.
• Scientific Reports (Nature Portfolio)minorStrategic or Co-development Partner · 1 January 2025TropIQ published collaborative research in Scientific Reports on the mosquitocidal activity of isoxazoline derivatives, demonstrating potent and rapid mosquitocidal effects.
• Radboud University Medical CentercoreStrategic or Co-development Partner · 1 January 2024TropIQ is a spin-off of Radboud University Medical Center, maintaining close ties to the academic institution for research collaboration and talent acquisition.
• Malaria Drug Accelerator ConsortiumcoreStrategic or Co-development Partner · 1 January 2024TropIQ is a proud contributor to the Malaria Drug Accelerator consortium, which focuses on prioritising targets for malaria drug discovery and accelerating the development of new antimalarial interventions.
• Science AdvancesminorStrategic or Co-development Partner · 1 January 2024TropIQ scientists co-authored a publication in Science Advances on PDE inhibitors for malaria treatment. The company contributed key data on transmission-blocking properties and helped unravel resistance mechanisms.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• IHMA (Infectious Disease Research): IHMA is a CRO specializing in infectious disease and anti-infective drug discovery services for the pharmaceutical industry. It is one of the closest direct peers to TropIQ given the shared focus on microbial and anti-parasitic screening services for pharma sponsors.

Broad incumbents

• Eurofins Scientific: Eurofins is a global testing and contract research services group with extensive pharma discovery and bioanalytical capabilities. It is comparable as a broad incumbent offering overlapping high-throughput screening and pharmacology services across many disease areas, including infectious disease.
• Charles River Laboratories: Charles River is a large CRO with end-to-end discovery and safety assessment services for pharma and biotech, including infectious disease models. It is a broad incumbent comparable to TropIQ on discovery services, though at much greater scale and breadth.
• WuXi AppTec: WuXi AppTec is a global CRO/CDMO offering discovery, preclinical, and chemistry services to pharma and biotech. It overlaps with TropIQ on small-molecule discovery and in vitro pharmacology capabilities, though it operates across all therapeutic areas at vastly larger scale.
• SGS Life Sciences: SGS provides clinical and bioanalytical laboratory services to pharmaceutical clients, including microbiology and cell-based assay capabilities. It is a broad incumbent whose laboratory service portfolio intersects with parts of TropIQ's screening and assay offering.
• Syngene International: Syngene is an Indian CRO providing integrated discovery, development, and manufacturing services to global pharma. It is comparable on discovery services and medicinal chemistry capabilities, though it serves a far broader therapeutic spectrum.

Others

• Medicines for Malaria Venture (MMV): MMV is a product development partnership focused on discovering and developing new antimalarial drugs. It is comparable thematically as a malaria drug-discovery ecosystem participant, though as a nonprofit PPP rather than a commercial CRO, and a likely TropIQ collaborator/funder.
• Drugs for Neglected Diseases initiative (DNDi): DNDi is a nonprofit R&D organization developing treatments for neglected tropical diseases, including malaria and leishmaniasis. It is thematically adjacent to TropIQ's vector-borne disease focus, though DNDi operates as a product developer rather than a service provider.
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines company. It is not a direct competitor but is included as an emerging biopharma player that may engage specialized CROs like TropIQ for novel infectious-disease screening and mechanism-of-action studies.
• Elanco Animal Health: Elanco is an animal health company with a portfolio that includes parasiticides and vector-control products (e.g., isoxazolines such as fluralaner). It is a potential TropIQ customer and ecosystem participant rather than a direct CRO competitor.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInnl.linkedin.com/company/tropiq-health-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TropIQ Health Sciences